Edwards Lifesciences Corp(EW) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 51.49 | EPS (ttm) | 1.69 | Insider Own | 1.22% | Shs Outstand | 576.6M | Perf Week | -4.46% |
| Market Cap | 50.01B | Forward P/E | 25.63 | EPS next Y | 12.8% | Insider Trans | -2.56% | Shs Float | 569.4M | Perf Month | -7.36% |
| Enterprise Value | 46.57B | PEG | 1.83 | EPS next Q | 0.74 | Inst Own | 94.48% | Short Float | 1.8% | Perf Quarter | 0.92% |
| Income | 0.98B | P/S | 7.68 | EPS this Y | 17.22% | Inst Trans | 1.44% | Short Ratio | 2.44 | Perf Half Y | 1.97% |
| Sales | 6.51B | P/B | 4.71 | EPS next 5Y | 14.02% | ROA | 7.16% | Short Interest | 10.24M | Perf YTD | 1.78% |
| Book/sh | 18.41 | P/C | 11.75 | EPS past 3/5Y | -9.46% 6.79% | ROE | 9.26% | 52W High | -9.89% ($96.29) | Perf Year | 10.85% |
| Cash/sh | 7.38 | P/FCF | 34.89 | Sales past 3/5Y | 4.08% 6.7% | ROIC | 8.67% | 52W Low | 20.01% ($72.30) | Perf 3Y | 17.15% |
| Dividend Est. | - | EV/EBITDA | 23.01 | EPS Y/Y TTM | 15.09% | Gross Margin | 78.28% | Volatility(W/M) | 2.23% 1.99% | Perf 5Y | -28.22% |
| Dividend TTM | - | EV/Sales | 7.15 | Sales Y/Y TTM | 14.55% | Oper. Margin | 28.53% | ATR (14) | 2.06 | Perf 10Y | 127.15% |
| Dividend Ex-Date | - | Quick Ratio | 3.77 | EPS Q/Q | -27.06% | Profit Margin | 15.05% | RSI (14) | 38.17 | Recom | 1.52 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.52 | Sales Q/Q | 13.63% | SMA20 | -3.69% ($90.09) | Beta | 0.86 | Target Price | $102.17 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/7/23 | SMA50 | -2.92% ($89.38) | Rel Volume | 0.54 | Prev Close | $86.18 |
| Employees | 16000 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 4.97% 2.4% | SMA200 | 2.11% ($84.98) | Avg Volume(3M) | 4.20M | Price | $86.77 |
| IPO | 2000/3/27 | Option/Short | Yes/Yes | Trades | 24654 | Volume | 2,269,692 | Change | 0.68% |
Company
EW is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global leading medical device company specializing in heart valve disease treatment. Founded in the United States in 1958 by Miles Lowell Edwards and headquartered in Irvine, California, the company holds a leading position in the structural heart disease treatment device market, including transcatheter aortic valve replacement (TAVR).
Over the past 1 year, roughly in the middle
10% below its 1-year high.
EW makes money exceptionally well
28.53% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.2% this year.
Tap to view numbers
The price looks about right
Trading at 51.5 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +17.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 94.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IHI 0.05%
AGNG 0.03%
GDOC 0.03%
MDEV 0.02%
FMED 0.02%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
EMLP 4.2B
QCLN 568M
PBW 384M
SMOG 135M
PBD 129MIt ranks #4 in the industry
Based on market cap of $50B.
EW $50B PER 51.5
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
FAQ
What kind of company is EW?
EW belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of EW?
The market cap of EW is approximately $50.0B, ranking 322 within its sector.
What is the P/E ratio of EW?
EW has a P/E ratio of approximately 51.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for EW?
EW has recorded a 52-week high of $96.29 and a low of $72.30.
